Recent Posts
- Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
- Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
- PharmaPhorum: Viva in vivo – The next generation of cell therapy is fast approaching
- Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
- Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma
Recent Comments
No comments to show.